selected publications
-
Adrenal Metastasectomy in the Presence and Absence of Extraadrenal Metastatic Disease.
Annals of surgery.
2019
Academic Article
GET IT
Times cited: 24 -
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.
Journal of the National Cancer Institute.
2019
Academic Article
GET IT
Times cited: 98 -
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Cancer research.
2018
Academic Article
GET IT
Times cited: 226 -
Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2018
Academic Article
GET IT
Times cited: 87 -
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 165 -
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2018
Academic Article
GET IT
Times cited: 121 -
Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.
The Journal of thoracic and cardiovascular surgery.
2018
Academic Article
GET IT
Times cited: 30 -
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Proceedings of the National Academy of Sciences of the United States of America.
2018
Academic Article
GET IT
Times cited: 184 -
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2018
Information Resource
GET IT
Times cited: 54 -
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
The New England journal of medicine.
2018
Article
GET IT
Times cited: 43 -
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 379 -
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
Annals of oncology : official journal of the European Society for Medical Oncology.
2018
Academic Article
GET IT
Times cited: 345 -
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.
Cancer immunology research.
2018
Academic Article
GET IT
Times cited: 270 -
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.
Proceedings of the National Academy of Sciences of the United States of America.
2018
Academic Article
GET IT
Times cited: 42 -
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
2018
Academic Article
GET IT
Times cited: 640 -
Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.
The Annals of thoracic surgery.
2018
Academic Article
GET IT
Times cited: 21 -
Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.
Lung cancer (Amsterdam, Netherlands).
2018
Academic Article
GET IT
Times cited: 39 -
Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition.
Advances in radiation oncology.
2018
Academic Article
GET IT
Times cited: 36 -
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
The New England journal of medicine.
2018
Academic Article
GET IT
Times cited: 1434 -
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Cancer cell.
2018
Academic Article
GET IT
Times cited: 778 -
Immunotherapy in surgically resectable non-small cell lung cancer.
Journal of thoracic disease.
2018
Information Resource
GET IT
Times cited: 50 -
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 1060 -
KEYNOTE-024: Unlocking a pathway to lung cancer cure?.
The Journal of thoracic and cardiovascular surgery.
2017
Editorial Article
GET IT
Times cited: 5 -
Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy.
Clinical lung cancer.
2017
Academic Article
GET IT
Times cited: 11 -
Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer.
Translational lung cancer research.
2017
Information Resource
GET IT
Times cited: 23 -
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.
Lung cancer (Amsterdam, Netherlands).
2017
Academic Article
GET IT
Times cited: 44 -
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
Cancer discovery.
2017
Academic Article
GET IT
Times cited: 490 -
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
2017
Academic Article
GET IT
Times cited: 500 -
Definitive Radiotherapy for Local Recurrence of NSCLC After Surgery.
Clinical lung cancer.
2017
Academic Article
GET IT
Times cited: 16 -
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2016
Academic Article
GET IT
Times cited: 858 -
Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.
Oncotarget.
2016
Academic Article
GET IT
Times cited: 19 -
Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.
Lung cancer (Amsterdam, Netherlands).
2016
Academic Article
GET IT
Times cited: 47 -
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
The Lancet. Oncology.
2016
Academic Article
GET IT
Times cited: 558 -
Utility of Routine PET Imaging to Predict Response and Survival After Induction Therapy for Non-Small Cell Lung Cancer.
The Annals of thoracic surgery.
2016
Academic Article
GET IT
Times cited: 27 -
Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2015
Academic Article
GET IT
Times cited: 36 -
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2015
Information Resource
GET IT
Times cited: 101 -
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2015
Academic Article
GET IT
Times cited: 81 -
Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 187 -
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.
Clinical lung cancer.
2014
Academic Article
GET IT
Times cited: 36 -
Serpins promote cancer cell survival and vascular co-option in brain metastasis.
Cell.
2014
Academic Article
GET IT
Times cited: 641 -
Chemotherapy for lung cancers: here to stay.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
2014
Information Resource
GET IT
Times cited: 5 -
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Science translational medicine.
2013
Academic Article
GET IT
Times cited: 465 -
Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers.
Cancer chemotherapy and pharmacology.
2013
Academic Article
GET IT
Times cited: 1 -
Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2013
Academic Article
GET IT
Times cited: 114 -
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.
Cancer chemotherapy and pharmacology.
2013
Academic Article
GET IT
Times cited: 14 -
EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
Molecular cancer therapeutics.
2013
Academic Article
GET IT
Times cited: 395 -
Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2013
Academic Article
GET IT
Times cited: 26 -
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2012
Academic Article
GET IT
Times cited: 128 -
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
2012
Academic Article
GET IT
Times cited: 93 -
Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2012
Academic Article
GET IT
Times cited: 41 -
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
Cancer.
2012
Academic Article
GET IT
Times cited: 126 -
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2012
Academic Article
GET IT
Times cited: 408 -
The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement.
Journal of the National Comprehensive Cancer Network : JNCCN.
2012
Information Resource
GET IT
Times cited: 52 -
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Molecular cancer therapeutics.
2011
Academic Article
GET IT
Times cited: 182 -
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011
Academic Article
GET IT
Times cited: 377 -
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011
Academic Article
GET IT
Times cited: 61 -
Genetics of vascular anomalies: an update.
Lymphatic research and biology.
2003
Information Resource
GET IT
Times cited: 2 -
Prenatal diagnosis of vascular anomalies: update and review of the literature.
Lymphatic research and biology.
2003
Information Resource
GET IT
Times cited: 5